| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNNC2 |
| Uniprot No | P02585 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-160aa |
| 氨基酸序列 | TDQQAEARSYLSEEMIAEFKAAFDMFDADGGGDISVKELGTVMRMLGQTPTKEELDAIIEEVDEDGSGTIDFEEFLVMMVRQMKEDAKGKSEEELAECFRIFDRNADGYIDPEELAEIFRASGEHVTDEEIESLMKDGDKNNDGRIDFDEFLKMMEGVQ |
| 预测分子量 | 45.0kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNNC2重组蛋白的模拟参考文献(非真实文献，仅供参考格式和内容方向)：
---
1. **标题**: *Cloning and Expression of Human Fast Skeletal Troponin C (TNNC2) in Escherichia coli*
**作者**: Hoffmann, J., et al.
**摘要**: 本研究报道了通过RT-PCR从人类骨骼肌中克隆TNNC2基因，并成功在大肠杆菌中表达重组蛋白。通过离子交换层析纯化后，圆二色谱分析显示重组TNNC2具有典型的钙结合蛋白构象，为后续功能研究奠定基础。
2. **标题**: *Structural Analysis of Recombinant TNNC2 Using NMR Spectroscopy*
**作者**: Gagné, S.M., & Sykes, B.D.
**摘要**: 利用核磁共振(NMR)技术解析了重组TNNC2蛋白的溶液结构，揭示了其钙离子结合域的特异性构象变化。研究表明，TNNC2的N端结构域在钙结合后发生显著构象重排，解释了其在肌肉快速收缩中的调控机制。
3. **标题**: *Functional Characterization of TNNC2 Mutants on Calcium Sensitivity*
**作者**: Dong, W., et al.
**摘要**: 通过定点突变技术构建了TNNC2的多个突变体重组蛋白，并利用体外肌动球蛋白ATP酶活性实验评估其对钙敏感性的影响。发现第89位天冬氨酸突变显著降低钙亲和力，提示该残基在信号转导中的关键作用。
4. **标题**: *TNNC2 Recombinant Protein as a Biomarker for Congenital Myopathies*
**作者**: Mogensen, J., et al.
**摘要**: 研究探讨了重组TNNC2蛋白在先天性肌病诊断中的应用，发现特定患者的TNNC2突变体会导致异常的钙解离动力学，提示其可作为分子诊断靶点。
---
**注意**：以上文献信息为模拟生成，实际文献需通过PubMed、Google Scholar等平台检索关键词如“TNNC2 recombinant protein”“skeletal troponin C expression”获取。
**Background of TNNC2 Recombinant Protein**
TNNC2. also known as Troponin C type 2. is a calcium-binding subunit of the troponin complex that regulates skeletal muscle contraction in fast-twitch muscle fibers. This protein is encoded by the *TNNC2* gene and is specifically expressed in skeletal muscle, distinguishing it from TNNC1. its cardiac muscle counterpart. The troponin complex, comprising TNNC (C subunit), TNNI (inhibitory subunit), and TNNT (tropomyosin-binding subunit), plays a central role in calcium-dependent muscle activation. TNNC2 undergoes conformational changes upon binding calcium ions, which relieves inhibition of actomyosin ATPase, enabling muscle contraction.
Recombinant TNNC2 is produced using biotechnological methods, typically involving the expression of the cloned *TNNC2* gene in bacterial (e.g., *E. coli*) or eukaryotic systems. This approach ensures high purity and scalability, critical for research and therapeutic applications. Recombinant TNNC2 retains native structural and functional properties, including calcium-binding capacity and interactions with other troponin subunits.
Research on TNNC2 focuses on understanding muscle physiology, particularly in conditions like muscular dystrophy, myopathies, or exercise-induced adaptation. It also serves as a tool for drug discovery, such as screening compounds targeting skeletal muscle dysfunction. Additionally, recombinant TNNC2 aids in structural studies (e.g., X-ray crystallography) to elucidate calcium signaling mechanisms. Abnormal TNNC2 expression or mutations are linked to skeletal muscle disorders, highlighting its diagnostic and therapeutic relevance.
Overall, TNNC2 recombinant protein is a vital resource for advancing muscle biology research and developing targeted therapies for neuromuscular diseases. Its study bridges molecular insights with clinical applications, emphasizing its role in both basic science and translational medicine.
×
